KDEV Karolinska Development AB

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota remains the CEO of Karolinska Development.

Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a clinical phase 1b/2a study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Based on compelling preclinical data, the company also intends to develop golexanolone as a potential treatment for Parkinson’s disease.

Viktor Drvota succeeds Anders Karlsson, who has served as CEO of Umecrine Cognition since August 2022. Viktor Drvota remains the CEO of Karolinska Development and will allocate his time equally on a 50/50 basis.

”Both Umecrine Cognition and Karolinska Development are highly effective organizations with experienced and specialized teams. This will be a cost-efficient approach to advancing the companies, and I look forward to dedicating focused attention to one of our largest holdings. I would also like to express my gratitude to Anders Karlsson for his contributions over the past years, particularly his pivotal role in establishing Umecrine Cognition’s international visibility”, says Viktor Drvota, CEO of Karolinska Development and Umecrine Cognition.

Karolinska Development’s ownership in Umecrine Cognition amounts to 73%.



For further information, please contact: 

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:  

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB

Phone: 6, e-mail:  



TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit .

Attachment



EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE

Karolinska Development’s portfolio company Umecrine Cognition publishe...

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate golexanolone provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in the scientific journal Frontiers in Immunology, support a key mechanism for golexanolone in alleviating symptoms of Parkinson’s disease,...

 PRESS RELEASE

Karolinska Developments portföljbolag Umecrine Cognition publicerar da...

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger ihållande reversering av neuroinflammation i en sjukdomsmodell av Parkinson. Resultaten, som publiceras i den vetenskapliga tidskriften Frontiers in Immunology, belyser verkningsmekanismen för golexanolon vid lindring av symtomen av Parkinsons sjukdom, v...

 PRESS RELEASE

Interim Report - January-June 2025

Interim Report - January-June 2025 STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. “We have a clear strategy and a stable scientific foundation for all of the projects in our investment portfolio, and will navigate these choppy market waters by keeping our focus on patient benefit”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the second quarter The portfolio company Umecrine Cognition presented recent preclinical da...

 PRESS RELEASE

Delårsrapport för januari – juni 2025

Delårsrapport för januari – juni 2025 STOCKHOLM – den 29 augusti 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – juni 2025. Den fulla rapporten är tillgänglig på bolagets hemsida. ” Vi har en tydlig strategi och en stabil vetenskaplig grund för samtliga projekt i vår investeringsportfölj och genom att hålla fokus på patientnyttan navigerar vi oss genom tider av turbulens”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under andra kvartalet Portföljbolaget Umecrine Cognition presenterade nya prekliniska data...

 PRESS RELEASE

Karolinska Development's portfolio company Modus Therapeutics raises S...

Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease. Modus Therapeutics, listed on Nasdaq First North Growth Market, has successfully c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch